Latest Period
Q2 2026
Security Snapshot
Intellia Therapeutics, Inc. - COMMON STOCK (NTLA) Institutional Ownership
CUSIP: 45826J105
13F Institutional Holders and Ownership History from Q1 2016 to Q2 2026
Institutions Reporting
326
Shares (Excl. Options)
143,874,926
Price
$16.92
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- NTLA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 143,874,926
- Total 13F value
- $2,433,089,062
- Portfolio coverage rank
- 0%
- Share change
- +33,479,183
- Value change
- +$569,832,189
- Number of holders
- 326
- Shares outstanding
- 135,808,632
- SEC-reported price per share
- $11.09
- Insider filing price
- $11.09
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NTLA - Intellia Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 45826J105.
- 326 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 304 to 326 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,414,593,940 to $2,433,089,062.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 326 institutions filings for Q2 2026.
Security key
45826J105
Latest holder period
Q2 2026
13F holders
326
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
NTLA full holder history
Intellia Therapeutics, Inc. SEC filings
Intellia Therapeutics, Inc. company facts
Intellia Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45826J105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
NTLA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARK Investment Management LLC | 12% | +11% | $127,723,843 | +$20,570,433 | 14,207,324 | +19% | ARK Investment Management LLC | 31 Dec 2025 |
| STATE STREET CORP | 6.8% | +22% | $131,321,515 | +$40,045,667 | 9,234,987 | +44% | STATE STREET CORPORATION | 30 Jun 2026 |
| BlackRock, Inc. | 8.2% | $70,244,546 | 8,453,014 | BlackRock, Inc. | 31 Mar 2025 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.3% | $80,330,210 | 6,266,007 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $76,222,220 | 5,945,571 | Vanguard Capital Management | 31 Mar 2026 | |||
| GOLDMAN SACHS GROUP INC | 2.7% | -48% | $36,086,548 | -$26,758,590 | 3,157,178 | -43% | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 |
| Contrarius Investment Management Ltd | 0.6% | -82% | $8,166,506 | -$59,155,462 | 714,480 | -88% | Contrarius Investment Management Ltd | 31 Dec 2025 |
As of 30 Jun 2026, 326 institutional investors reported holding 143,874,926 shares of Intellia Therapeutics, Inc. - COMMON STOCK (NTLA). This represents 106% of the company’s total 135,808,632 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
83%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 12% | 16,875,684 | +16% | 1.9% | $285,536,575 |
| BlackRock, Inc. | 11% | 15,409,023 | +27% | 0% | $260,720,664 |
| STATE STREET CORP | 6.8% | 9,234,987 | +33% | 0% | $156,255,980 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.4% | 7,332,401 | +18% | 0.01% | $124,064,225 |
| D. E. Shaw & Co., Inc. | 4.7% | 6,443,323 | +12% | 0.07% | $109,021,025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 6,028,586 | +19% | 0% | $102,003,675 |
| TWO SIGMA INVESTMENTS, LP | 3.9% | 5,235,348 | +11% | 0.07% | $88,582,088 |
| FMR LLC | 3.5% | 4,773,034 | +131% | 0% | $80,759,741 |
| RA CAPITAL MANAGEMENT, L.P. | 3.3% | 4,526,926 | 0.67% | $76,595,588 | |
| REGENERON PHARMACEUTICALS, INC. | 2.7% | 3,702,995 | 0% | 35% | $62,654,675 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 3,631,061 | +27% | 0% | $61,449,402 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.4% | 3,280,760 | +135% | 0.02% | $55,510,459 |
| Sumitomo Mitsui Trust Group, Inc. | 2.1% | 2,897,529 | +47% | 0.03% | $49,026,191 |
| Amova Asset Management Americas, Inc. | 2.1% | 2,897,529 | +47% | 0.63% | $49,026,191 |
| DIMENSIONAL FUND ADVISORS LP | 1.9% | 2,602,944 | +12% | 0.01% | $44,038,979 |
| GOLDMAN SACHS GROUP INC | 1.7% | 2,264,471 | +39% | 0% | $38,314,849 |
| UBS Group AG | 1.6% | 2,152,912 | -20% | 0.01% | $36,427,270 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.5% | 2,066,356 | +28% | 0.15% | $34,962,744 |
| Contrarius Group Holdings Ltd | 1.4% | 1,955,228 | +2.3% | 1.5% | $33,082,458 |
| JUPITER ASSET MANAGEMENT LTD | 1.4% | 1,849,507 | +3.8% | 0.16% | $31,293,658 |
| MORGAN STANLEY | 1.3% | 1,731,904 | -17% | 0% | $29,303,820 |
| ARMISTICE CAPITAL, LLC | 1.1% | 1,500,000 | +346% | 0.7% | $25,380,000 |
| RENAISSANCE TECHNOLOGIES LLC | 1% | 1,400,004 | 0.03% | $23,688,068 | |
| NORTHERN TRUST CORP | 0.94% | 1,272,136 | +32% | 0% | $21,524,541 |
| HRT FINANCIAL LP | 0.92% | 1,243,317 | +148% | 0.04% | $21,036,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Latest
Q2 2026
Rows shown
1-25 of 42
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 143,874,926 | $2,433,089,062 | +$569,832,189 | $16.92 | 326 |
| 2026 Q1 | 110,440,249 | $1,414,593,940 | +$111,595,025 | $12.82 | 304 |
| 2025 Q4 | 104,157,595 | $936,396,181 | -$52,722,083 | $8.99 | 291 |
| 2025 Q3 | 104,167,644 | $1,798,715,383 | +$103,219,618 | $17.27 | 280 |
| 2025 Q2 | 99,520,897 | $933,579,792 | -$6,825,658 | $9.38 | 277 |
| 2025 Q1 | 101,252,381 | $719,981,345 | +$1,659,582 | $7.11 | 289 |
| 2024 Q4 | 99,191,549 | $1,156,525,724 | -$49,302,844 | $11.66 | 288 |
| 2024 Q3 | 93,188,112 | $1,914,885,599 | +$52,687,081 | $20.55 | 277 |
| 2024 Q2 | 90,118,237 | $2,016,932,908 | -$33,057,144 | $22.38 | 286 |
| 2024 Q1 | 90,994,794 | $2,502,941,003 | +$158,724,377 | $27.51 | 279 |
| 2023 Q4 | 85,253,157 | $2,599,308,572 | +$153,798,142 | $30.49 | 289 |
| 2023 Q3 | 80,150,230 | $2,534,451,262 | +$57,616,066 | $31.62 | 281 |
| 2023 Q2 | 78,283,933 | $3,190,579,654 | -$9,432,957 | $40.78 | 288 |
| 2023 Q1 | 78,716,838 | $2,928,484,579 | +$27,166,066 | $37.27 | 288 |
| 2022 Q4 | 78,108,132 | $2,724,660,295 | +$325,216,887 | $34.89 | 294 |
| 2022 Q3 | 68,149,786 | $3,811,906,455 | -$6,962,154 | $55.96 | 308 |
| 2022 Q2 | 67,593,487 | $3,442,253,307 | +$98,077,804 | $51.76 | 282 |
| 2022 Q1 | 65,174,223 | $4,718,129,955 | -$27,349,229 | $72.67 | 341 |
| 2021 Q4 | 64,197,108 | $7,594,973,150 | +$200,734,926 | $118.24 | 361 |
| 2021 Q3 | 62,179,774 | $8,341,966,333 | +$38,202,306 | $134.15 | 354 |
| 2021 Q2 | 61,943,081 | $10,039,072,441 | +$39,075,135 | $161.91 | 329 |
| 2021 Q1 | 62,997,292 | $5,055,620,165 | +$268,264,167 | $80.25 | 255 |
| 2020 Q4 | 61,851,171 | $3,364,841,363 | +$187,799,640 | $54.40 | 239 |
| 2020 Q3 | 56,492,124 | $1,125,276,243 | +$49,648,218 | $19.88 | 161 |
| 2020 Q2 | 53,928,267 | $1,127,243,500 | +$160,801,520 | $21.02 | 160 |